<!doctype html><html lang="en"><head><meta charset="utf-8"> <title>Life after Eroom’s law | Refoundable</title> <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover"> <meta name="description" content="Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the near frontiers of drug discovery."> <meta name="theme-color" content="#061E29"> <link rel="alternate" href="/feed.xml" type="application/atom+xml"> <link rel="apple-touch-icon" href="/apple-touch-icon.png"><link rel="icon" href="/favicon.png" type="image/png"><link rel="icon" href="data:image/svg+xml;utf8,%3Csvg%20width%3D'256'%20height%3D'256'%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%3E%3Cg%20fill%3D'none'%20fill-rule%3D'evenodd'%3E%3Cpath%20fill%3D'%23061E29'%20d%3D'M0%200h256v256H0z'%2F%3E%3Cpath%20d%3D'M113.2%20113H87V63.4H136c10.3%200%2020.9.2%2029.9%206a34.8%2034.8%200%200114.8%2029c0%2013.2-7.7%2025.4-20.2%2030l26.9%2065h-30L134%20133.9H73l-15.6-19.1h70.7c5.7%200%2011.9.5%2016.8-2.4%204.5-2.7%206.9-8.2%206.9-13.3%200-4.6-2.8-9.6-6.7-12-4.6-2.9-12.5-2.2-17.6-2.2h-14.4v28zm1%2022.7v44.2H86.8v-44.2H114z'%20fill%3D'%23FFF'%2F%3E%3C%2Fg%3E%3C%2Fsvg%3E" sizes="any" type="image/svg+xml"><link rel="mask-icon" href="/mask-icon.svg" color="#061E29"> <link rel="manifest" href="/manifest.json"> <style>:root{--fontstack-prefix:-apple-system,BlinkMacSystemFont,;--fontstack-sans-serif:"Helvetica Neue",sans-serif;--fontstack-serif:Georgia,serif;--fontstack-monospace:Menlo,Consolas,monospace;--fontstack-default:var(--fontstack-prefix) var(--fontstack-sans-serif);--font-size:1.6vw;--font-features:"halt","ss01","ss02";--line-height:calc(20 / 14);--heading-letter-spacing:-.04em;--breakpoint-lg:1600px;--breakpoint-md:1080px;--breakpoint-sm:640px;--breakpoint-xs:400px;--space-lg:24vw;--space-md:8vw;--space-sm:4vw;--space-xs:1.2vw;--border-lg:4px;--border-md:2px;--border-sm:1px;--link-color:#03549b;--background-color:#fff;--text-color:#000;--code-color:#3914b3;--nav-padding:.75vmax;--nav-item-space:1.4vmax}*,::after,::before{padding:0;margin:0;box-sizing:border-box}html{font-size:100%;-webkit-text-size-adjust:none;-ms-text-size-adjust:none;text-size-adjust:none;text-rendering:optimizelegibility;image-rendering:optimizequality;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;background:var(--bg-color)}body{--space-body:var(--space-lg);padding-top:0;padding-bottom:0;padding-left:var(--space-body);padding-right:var(--space-body);margin:0 auto 0;font-family:var(--fontstack-default);font-size:var(--font-size);font-feature-settings:var(--font-features);line-height:var(--line-height);hanging-punctuation:first allow-end;color:var(--text-color);background:var(--bg-color);-webkit-transition:all .2s ease;transition:all .2s ease}@media (max-width:1080px){body{--space-body:var(--space-md);font-size:calc(var(--font-size) * 1.4)}}@media (max-width:640px){body{--space-body:var(--space-sm);font-size:calc(var(--font-size) * 2.4)}}@media (max-width:400px){body{font-size:calc(var(--font-size) * 3.2)}}a{color:var(--text-color);text-decoration:none;-webkit-transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease;transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease}a:focus,a:hover{-webkit-transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;text-decoration:underline}hr,img{border:0}::-webkit-input-placeholder{color:var(--text-color);opacity:.2}::-moz-placeholder{color:var(--text-color);opacity:.2}:-ms-input-placeholder{color:var(--text-color);opacity:.2}::-ms-input-placeholder{color:var(--text-color);opacity:.2}:focus::-webkit-input-placeholder{color:var(--link-color)}:focus::-moz-placeholder{color:var(--link-color)}:focus:-ms-input-placeholder{color:var(--link-color)}:focus::-ms-input-placeholder{color:var(--link-color)}.navigation{padding-top:var(--nav-padding);padding-bottom:var(--nav-padding);margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:90%;font-weight:700}.navigation li{display:inline-block;line-height:2}.navigation li a{padding:.5em var(--nav-item-space)}.navigation li a:focus,.navigation li a:hover{color:var(--link-color);text-decoration:none}.content{margin-bottom:16vmin}.content::after,.content::before{display:table;content:""}.content::after{clear:both}.content article>:last-child{margin-bottom:0!important}.content a{font-weight:700}.content a:has(>code){-webkit-text-decoration-color:var(--code-color);text-decoration-color:var(--code-color)}.content p{margin-bottom:1.6rem;line-height:calc(var(--line-height) * 1.2)}.content h2,.content h3{margin:10vmin 0 1rem;font-size:72%;font-weight:400;opacity:.5}.content ol,.content ul{margin-bottom:1.8rem;list-style:none;counter-reset:list}@media (max-width:640px){.content ol,.content ul{margin-left:1em}}.content ol li,.content ul li{line-height:calc(var(--line-height) * 1.2)}.content ol li::before,.content ul li::before{position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none}.content ul li::before{content:"-";padding-right:.5em}.content ol li::before{counter-increment:list;content:counter(list) ".";padding-right:.25em}.content img{--space-deco:var(--space-md);display:block;width:calc(100% + var(--space-deco) * 2);margin-left:calc(var(--space-deco) * -1);margin-right:calc(var(--space-deco) * -1);margin-bottom:1.8rem}@media (max-width:1080px){.content img{--space-deco:var(--space-md)}}@media (max-width:640px){.content img{--space-deco:var(--space-sm)}}.content hr::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.content sup{font-size:75%}.footnotes{font-size:80%}.footnotes::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.footer{padding:0 0 16vmin;margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:80%;text-transform:lowercase}.footer ul li{display:inline-block;line-height:1.8}.footer ul li a{padding:.5em var(--nav-item-space)}@media print{*,::after,::before{background:0 0!important;color:#000!important;box-shadow:none!important;text-shadow:none!important}body{padding:10mm!important;margin:0!important;font-size:calc(var(--font-size) * 1.35)}a,a:visited{text-decoration:none}img{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.footer,.navigation{display:none}}:root{--rdmz-h:var(--code-color-h, 253.962264151);--rdmz-s:var(--code-color-s, 79.8994974874%);--rdmz-l:var(--code-color-l, 39.0196078431%)}body,html{max-width:100%;overflow-x:hidden}body{height:100%;width:100%;margin:0}.content{margin-bottom:0}.content h2,.content h3{opacity:1;margin:0}.content ul li::before{content:"\2022"}.content hr::before{margin:0 auto;height:0;width:0}.content a,.navigation,a,figcaption,ol li,p,span,ul li{font-weight:var(--reg-w)}.essay .head,.essay .rubric,.essay .title,.essay .title a,.essay h2,.essay h2 a,.essay h3{font-weight:var(--sem-w)!important}.essay .cta,.essay .cta a,.essay figure figcaption{font-weight:var(--reg-w)!important}a{color:var(--m-blue)}a:focus::-webkit-input-placeholder{color:var(--m-blue)}a:focus::-moz-placeholder{color:var(--m-blue)}a:focus:-ms-input-placeholder{color:var(--m-blue)}a:focus::-ms-input-placeholder{color:var(--m-blue)}.navigation,a{letter-spacing:var(--txt-ls)}.essay .title,.essay .title a,.essay h2{letter-spacing:var(--met-ls)}.essay .head,.essay h3{letter-spacing:var(--hed-ls)}.essay .cta,.essay .cta a,.essay .deck,.essay ol li,.essay p{letter-spacing:var(--txt-ls)}.essay figure .credits{font-size:95%}.essay .rubric{color:var(--m-accent)}.essay .title,.essay .title a{color:var(--xm-silver)}.essay .head{color:var(--x-black)}.essay .cta{color:var(--m-blue)}.essay ol li,.essay p{color:var(--xm-black)}.essay figure figcaption{color:var(--m-gray)}.essay figure .credits{color:var(--x-silver)}.essay .head{line-height:1}.essay .deck,.essay ol li,.essay p{line-height:1.35}.essay .footnotes p{line-height:1.5}.essay .title{text-decoration:none}.essay .rubric{text-transform:uppercase}.essay ol li{margin-bottom:.3em}.essay hr{padding:0 0 8vw}.callout,.essay-nav,.footer,.navigation,figure figcaption{text-align:center}.txt-wrap{white-space:nowrap}.navigation{margin:var(--nil) var(--full-wid);background-color:var(--x-black);padding:0}.navigation li{padding:.5em 0}.navigation li a{color:var(--xx-white)}.navigation li a:focus,.navigation li a:hover{color:var(--xm-silver)!important}.navigation #logomark a svg{width:1.2em;height:1.2em;margin-bottom:-.15rem}.rg-aro{border-right:1px solid;border-bottom:1px solid}.bo-aro{border-right:1.5px solid;border-bottom:1.5px solid}.tp-aro{height:.5em;width:.5em;display:inline-block}.sh-aro{height:.4em;width:.4em;display:inline-block}.blu-aro{color:var(--m-blue)}.slv-aro{color:var(--xxx-silver)}.d-aro{-webkit-transform:rotate(45deg);transform:rotate(45deg)}.u-aro{-webkit-transform:rotate(-135deg);transform:rotate(-135deg)}.ext-aro-bs{position:relative;display:inline-block;vertical-align:middle;color:var(--m-blue);box-sizing:border-box}.ext-aro-bs:after,.ext-aro-bs:before{content:"";box-sizing:border-box}.ext-aro-fo{width:.45em;height:.45em;border-width:1px 1px 0 0;border-style:solid;margin:0 0 1px .3em}.ext-aro-fo:before{right:0;top:-1px;position:absolute;height:1px;box-shadow:inset 0 0 0 32px;-webkit-transform:rotate(-45deg);transform:rotate(-45deg);width:.7em;-webkit-transform-origin:right top;transform-origin:right top}.fn-ext-lnk{margin-left:.15em}.essay-nav{font-size:82%;margin:var(--nil) var(--full-wid) -5vh;padding:0;z-index:1;border-bottom:1px solid var(--x-silver)}.essay-nav ul{margin-bottom:0}.essay-nav ul li{display:inline-block;line-height:2;padding:.5em 0}.essay-nav ul li:before{display:none}.essay-nav a.sticky-btn{font-weight:var(--reg-w);padding:.3em 1em;margin:0 1em;color:var(--l-black);text-decoration:none;-webkit-transition:none;transition:none}.essay-nav a.sticky-btn:hover{opacity:.7}.essay{counter-reset:count-fn 0 count-qst 0;margin:0 auto}.essay .essay-header{padding:8vw 0}.essay .callout .rubric{margin:0 auto -1.5em;position:relative;top:-1.5em}.essay .callout .title{margin:0}.essay .callout .head{margin:0 0 .3em}.essay .callout .deck{margin:0 auto}.essay .callout .byline{display:none}.essay .callout .cta{margin:0;padding-top:.7rem}.essay .callout .cta a{padding-right:.2rem;padding-bottom:.2em;margin-left:1%}.essay .callout .po-aro{margin-bottom:.2em;margin-left:.2em}.essay .section-headings{position:relative;padding-top:8vw!important}.essay .section-headings .title a{text-decoration:none;padding:8vw 0 0}.essay .section-headings .head{max-width:65%}.essay figure figcaption{padding-top:.5rem;margin:auto}.essay figure .credits-blk{display:block}.essay .qst{margin-top:-3em;padding-top:4.2em;font-weight:var(--med-w)}.essay .qst::before{color:var(--m-gray);counter-increment:count-qst;content:counter(count-qst) ".";position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none;padding-right:.25em}.essay .qst-lnk{padding:.2em .3em!important;margin-right:-1.5em}.essay .qst-lnk svg{fill:var(--m-gray);opacity:.4;vertical-align:middle}.essay .fn-btn{background-color:var(--l-silver);position:relative;margin-left:.3em;color:var(--m-gray);font-weight:var(--sem-w);font-size:90%;text-decoration:none}.essay .fn-btn:hover{background-color:var(--xl-silver)}.essay .fn-btn:focus{outline:0}.essay .fn-btn-top{padding:.25em 1em .35em!important;top:.35em;margin-left:.2em}.essay .fn-btn-bot{padding:.35em .8em .3em!important;margin-left:.5em;top:.1em}.essay sup{padding-top:25vh;margin-top:-25vh}.essay .footnotes{font-size:inherit;padding-bottom:2.2vw;border-top:1px solid var(--m-silver);padding-top:2em}.essay .footnotes:before{display:none}.essay .footnotes ol li{display:-webkit-box;display:flex}.essay .footnotes ol li:before{color:var(--m-gray);position:relative;display:inline-block;counter-increment:count-fn;content:counter(count-fn) "."}.footer a,.footer p{margin:0 .2em;padding:0 .1em!important}.footer a,.footer p,.footer ul{display:inline-block;text-transform:capitalize}.footer ul li:before{content:" "!important;display:none}.footer .return-top{text-align:center;margin-bottom:6vh}.footer .return-top a{font-size:130%;text-decoration:none;padding:.15em .85em .25em!important;border-radius:7px;margin-left:.2em}.footer .return-top a:hover{text-decoration:none}.footer-light{padding:0;margin:4vh auto 3vh}.footer-light a,.footer-light p{color:var(--xxx-silver)}.footer-light .return-top a{background-color:var(--l-silver)}.footer-light .return-top a:hover{background-color:var(--xl-silver)}:root{--reg-w:400;--med-w:500;--sem-w:600;--hed-ls:-.065em;--met-ls:-.04em;--txt-ls:-.025em;--lg-rubric:70%;--lg-title:210%;--lg-head:395%;--lg-deck:140%;--lg-cta:130%;--lg-bghead:440%;--lg-subhead:160%;--lg-bgcta:150%;--md-rubric:80%;--md-title:240%;--md-head:450%;--md-deck:160%;--md-cta:150%;--md-bghead:450%;--md-subhead:180%;--md-bgcta:170%;--sm-rubric:90%;--sm-title:230%;--sm-head:370%;--sm-deck:180%;--sm-cta:170%;--sm-bghead:430%;--sm-subhead:200%;--sm-bgcta:180%;--xs-rubric:65%;--xs-title:170%;--xs-head:280%;--xs-deck:130%;--xs-cta:130%;--xs-bghead:330%;--xs-subhead:155%;--xs-bgcta:140%;--lg-nav:90%;--md-nav:120%;--sm-nav:140%;--xs-nav:110%;--lg-txt:130%;--md-txt:150%;--sm-txt:170%;--xs-txt:130%;--lg-fn:100%;--mo-fn:80%;--lg-fig:90%;--md-fig:115%;--sm-fig:130%;--xs-fig:95%;--lg-not:110%;--md-not:140%;--sm-not:160%;--xs-not:120%;--lg-foo:80%;--md-foo:105%;--sm-foo:120%;--xs-foo:90%;--xx-black:#0d0d0d;--x-black:#111;--xm-black:#222;--m-black:#272727;--l-black:#333;--xl-black:#444;--m-gray:#555;--m-blue:#03549b;--xx-white:#fff;--xxx-silver:#898989;--xx-silver:#aaa;--x-silver:#bbb;--bf-silver:#bfbfbf;--xm-silver:#cfcfcf;--m-silver:#ddd;--l-silver:#eee;--xl-silver:#e7e7e7;--m-accent:#805e03;--vl-accent:#f6f6f6;--nil:0;--full-wid:-50%;--space-lg:21vw}@font-face{font-family:Barlow;font-style:normal;font-weight:400;src:local("Barlow Regular"),local("Barlow-Regular"),url(https://fonts.gstatic.com/s/barlow/v4/7cHpv4kjgoGqM7E_DMs5ynghnQ.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:Barlow;font-style:italic;font-weight:400;src:local("Barlow Italic"),local("Barlow-Italic"),url(https://fonts.gstatic.com/s/barlow/v4/7cHrv4kjgoGqM7E_Cfs7wH8Dnzcj.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:500;src:local("Barlow Medium"),local("Barlow-Medium"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E3_-gs51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:600;src:local("Barlow SemiBold"),local("Barlow-SemiBold"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E30-8s51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:system-ui;font-style:normal;font-weight:400;src:local(".SFNSText-Regular"),local(".HelveticaNeueDeskInterface-Regular"),local(".LucidaGrandeUI"),local("Segoe UI"),local("Ubuntu"),local("Roboto-Regular"),local("DroidSans"),local("Tahoma")}@font-face{font-family:system-ui;font-style:normal;font-weight:600;src:local(".SFNSText-Medium"),local(".HelveticaNeueDeskInterface-MediumP4"),local(".LucidaGrandeUI"),local("Segoe UI Semibold"),local("Ubuntu Medium"),local("Roboto-Medium"),local("DroidSans-Bold"),local("Tahoma Bold")}:root{--font-size:1.3vw;--fontstack-prefix:'Barlow','Barlow-Local',system-ui;--fontstack-sans-serif:'Barlow','Barlow-Local',system-ui,sans-serif}html{font-family:Barlow,Barlow-Local,system-ui,sans-serif}@media screen and (max-width:799px){.navigation li{padding:.6em .3em;margin:0 .5em 0 0}.essay-nav{display:none}.essay{max-width:100%}.essay p{max-width:94%;line-height:1.4}.essay ol,.essay p{margin-left:3%;margin-bottom:1.2em}.essay ol{max-width:97%;margin-left:0!important}.essay ol li{margin-left:1.5em;line-height:1.4}.essay .callout{margin:0 auto 6vw!important;padding:15% 0 20%}.essay .section-headings{margin-bottom:8vw;left:3%;max-width:100%}.essay figure{margin:11% auto 10%}.essay figure img{width:110%;margin-bottom:0}.essay figure figcaption{max-width:95%}.essay .qst{margin-top:-1.3em;padding-top:2em}.essay .qst::before{margin-left:0;margin-right:.6em;font-weight:var(--sem-w);width:1em;-webkit-box-pack:center;justify-content:center;text-align:center;padding-right:0;position:unset;display:inline-block}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin-top:10vw}.essay .footnotes ol li::before,.essay .footnotes p{font-size:var(--mo-fn)}.essay .footnotes p{margin-left:0;max-width:90%}.essay .footnotes ol li{margin-left:0;padding-top:11vh;margin-top:-11vh}.essay .footnotes ol li:before{margin-top:.05em;margin-left:-2.3em}.essay #deck-eroom{max-width:80%}.footer ul{margin-left:0}}@media screen and (max-width:400px){.navigation{font-size:var(--xs-nav)}.essay .rubric{font-size:var(--xs-rubric)}.essay .title,.essay h2{font-size:var(--xs-title)!important}.essay .head,.essay h3{font-size:var(--xs-head)}.essay .deck{font-size:var(--xs-deck)}.essay .cta{font-size:var(--xs-cta)}.essay ol li,.essay p{font-size:var(--xs-txt)}.essay figure{font-size:var(--xs-fig)}.footer{font-size:var(--xs-foo)}}@media screen and (min-width:401px) and (max-width:639px){.navigation{font-size:var(--sm-nav)}.essay .rubric{font-size:var(--sm-rubric)}.essay .title,.essay h2{font-size:var(--sm-title)!important}.essay .head,.essay h3{font-size:var(--sm-head)!important}.essay .deck{font-size:var(--sm-deck)!important}.essay .cta{font-size:var(--sm-cta)}.tp-aro{height:.6em;width:.6em}.essay ol li,.essay p{font-size:var(--sm-txt)}.essay figure{font-size:var(--sm-fig)}.footer{font-size:var(--sm-foo)}}@media screen and (min-width:640px) and (max-width:799px){.navigation{font-size:var(--md-nav)}.essay .rubric{font-size:var(--md-rubric)}.essay .title,.essay h2{font-size:var(--md-title)!important}.essay .head,.essay h3{font-size:var(--md-head)}.essay .deck{font-size:var(--md-deck)!important}.essay .cta{font-size:var(--md-cta)}.essay ol li,.essay p{font-size:var(--md-txt);margin-left:0}.essay figure{font-size:var(--md-fig)}.footer{font-size:var(--md-foo)}.tp-aro{height:.55em;width:.55em}.navigation li{margin:0 2em 0}.essay{max-width:95%}.essay ol li{margin-left:0}.essay p{max-width:100%}.essay .section-headings{margin-bottom:6vw;left:0}.essay figure img{width:100%;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:80%}.essay .qst::before{margin-top:0;margin-left:-4em;font-size:100%;font-weight:var(--reg-w);background-color:transparent;width:4em;-webkit-box-pack:end;justify-content:flex-end;text-align:right;padding-right:.25em;position:absolute;display:-webkit-box;display:flex}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin:10vw auto 0 -1.75em;max-width:100%}.essay .footnotes ol,.essay .footnotes p{max-width:100%;width:100%}.essay .footnotes ol li:before{margin-left:0;width:1.5em}.essay #deck-eroom{max-width:66%}}@media screen and (min-width:800px){.navigation{font-size:var(--lg-nav)}.essay .rubric{font-size:var(--lg-rubric)}.essay .title,.essay h2{font-size:var(--lg-title)!important}.essay .head,.essay h3{font-size:var(--lg-head)}.essay .deck{font-size:var(--lg-deck)!important}.essay .cta{font-size:var(--lg-cta)}.essay ol li,.essay p{font-size:var(--lg-txt)}.essay figure{font-size:var(--lg-fig)}.essay .footnotes ol li,.essay .footnotes p{font-size:var(--lg-fn)}.footer{font-size:var(--lg-foo)}.navigation li{padding:.5em 0}.navigation li a{padding:.3em 1em;margin:0 2.5em}.essay-nav{display:none}.essay{max-width:95%}.essay ol li,.essay p{max-width:86%;margin-left:5%}.essay .callout{margin:0 auto!important;padding:4% 0 10%}.essay .section-headings{margin-bottom:5vw;left:-1.5em}.essay figure{margin:10% auto 9%}.essay figure img{width:100%;max-width:1200px;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:65%}.essay .fn-btn{border-radius:7px}.essay .footnotes{max-width:100%;margin:8vw auto 0 .9em}.essay .footnotes ol li{padding-top:10vh;margin-top:-10vh;max-width:100%;margin-left:0}.essay .footnotes ol li p{margin-left:0}.essay .footnotes ol li:before{margin-left:-2.75em}.essay #deck-eroom{max-width:58%}}@media screen and (min-width:1080px){.essay-nav{display:block}.essay-nav-scroll{position:fixed!important;width:100%!important;top:0;left:50%;-webkit-transition:background-color .5s cubic-bezier(.28,.11,.32,1);transition:background-color .5s cubic-bezier(.28,.11,.32,1);border-bottom-color:var(--xl-black)!important;background-color:var(--l-black)!important}.essay-btn-scroll{color:var(--xl-silver)!important}.essay{max-width:93%}.essay ol li,.essay p{max-width:91%}.essay figure figcaption{max-width:70%}.essay #deck-eroom{max-width:61%}}</style> <link href="https://fonts.googleapis.com/css?family=Barlow:400,400i,500,600&amp;display=swap" rel="stylesheet"> <link rel="canonical" href="https://refoundable.com/eroom-private"> <meta property="og:type" content="article"> <meta property="og:site_name" content="Refoundable"> <meta property="og:title" content="Life after Eroom’s law"> <meta property="og:url" content="https://refoundable.com/eroom-private"> <meta property="og:description" content="Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the near frontiers of drug discovery."> <meta property="og:image" content="https://refoundable.com/assets/img/og-eroom.png"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@refoundable"> </head><body><nav id="top" class="navigation"> <ul> <li id="logomark"> <a href="/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 200"><path d="M85.7 76H45.2V0h75.6c16 0 32.2.3 46.1 9.1a53.5 53.5 0 0122.8 44.7 48.4 48.4 0 01-31.2 46.1L200 200h-46l-36.3-91.7H24L0 78.8h108.9c8.7 0 18.1.8 25.8-3.7a24.2 24.2 0 0010.5-20.5c0-7-4.2-14.7-10.3-18.3-7-4.5-19.2-3.4-27-3.4H85.6v43zm1.4 35v68.1h-42v-68h42z" fill="#FFF" fill-rule="evenodd"></path></svg></a> </li> <li> <a href="/mission">Mission</a> </li> <li> <a href="/soon">Research</a> </li> <li> <a href="/about">About</a> </li> </ul> </nav> <main class="content" role="main"> <script>window.onscroll=function(){window.addEventListener("scroll",stickyNav)}</script> <nav id="sticky-nav" class="essay-nav"> <ul> <li><a class="sticky-btn" href="#s1">Introduction</a></li> <li><a class="sticky-btn" href="#s2">Beginnings</a></li> <li><a class="sticky-btn" href="#s3">Stasis</a></li> <li><a class="sticky-btn" href="#s4">Frontiers</a></li> </ul> </nav> <article class="essay"> <div class="essay-header"> <div class="callout"> <div class="meta"> <div class="rubric">Interview&nbsp;&nbsp;•&nbsp;&nbsp;March XX, 2020</div> <div class="title">Secrets</div> </div> <h1 class="head">Life after<br>Eroom’s law.</h1> <p class="deck" id="deck-eroom">Jack Scannell, who coined Eroom's law, on the end of an era in drug R&amp;D, and the near&nbsp;frontiers of drug discovery.</p> <div class="byline"> <span>By John Strider</span><span>&nbsp;|&nbsp;</span> <span>Refoundable</span> </div> <div class="cta"><a href="#s1">Introduction</a><div class="rg-aro sh-aro blu-aro po-aro d-aro"></div></div> </div> </div>  <div class="section-headings"> <h2 class="title"><a id="s1">Introduction</a></h2> <h3 class="head">Looking past<br>the end.</h3> </div> <p>A founding proposition of Refoundable is that far too many people rationally choose to look for secrets in the few areas of technology that have seen the most progress over the last half-century, namely computers, finance, and possibly shale oil in the last decade.</p> <p>A necessary and counterintuitive approach at this point is to start with the technology areas worst hit by neglect, stagnation and rising costs, and figure out how to restart their <span class="txt-wrap">progress.<sup><a href="#fn1" id="r1" class="fn-btn fn-btn-top">1</a></sup></span></p> <p>Take healthcare for example. While computers got faster and cheaper every year over the last fifty years, healthcare costs rose up to four times faster than general inflation in the last twenty years <span class="txt-wrap">alone.<sup><a href="#fn2" id="r2" class="fn-btn fn-btn-top">2</a></sup></span></p> <p>Yet, unlike other stagnating technology areas, like defense or nuclear energy, most people agree that healthcare is both badly broken and absolutely vital to fix, so by starting there at least, fewer people might try to stop us.</p> <p>Of all the areas of healthcare one can look at, many fashionable and even unfashionable areas receive a fair deal of attention from venture capitalists and philanthropists at this point—sometimes, it’s hard to tell them apart—but one big area that has stagnated despite the scrutiny it is given is pharmaceuticals.</p> <p>The great promise of pharmacology was that by unlocking the secrets of biochemistry, you could create all kinds of life-saving and even life-enhancing concoctions, from a full-course-meal in a pill to a general cancer cure. Furthermore, progress in this area would open up new avenues of research in many ancillary fields, from nutrition and anti-aging to preventative medicine writ large. The more progress we’d make, the less effort we’d need to put in to uncover new secrets.</p> <p>Today’s pharma industry looks nothing of the sort. If anything, it looks to be moving in the opposite direction. We seem to know less and less with each passing day about human biology—except that it’s very, very complex—and the cures only seem to get harder and harder to find, so it’s only reasonable to ask: what went wrong?</p> <p>To help us along, the drug industry has a robust measure of progress that can begin to unravel the Gordian knot of its great stasis. It’s known as Eroom’s law, a name speaking volumes already. It’s literally an ironic backward spelling of Moore’s law—the benchmark of progress in the computer industry—so it strikes us as the most fitting place to start.</p> <p style="font-weight:500">Race to the bottom</p> <p>Eroom’s law is the observation that the cost of developing a new drug roughly doubled every nine years from 1950 through the 2010. All in all, it shows a roughly 80-fold decline in the productivity of drug R&amp;D.</p> <p>It’s hard to say what’s worse, the staggering decline or the fact that it went on unchecked for six decades. Either way, as the sum total of our efforts to look for life-saving secrets, Eroom’s law leaves no doubt that our ability to explore the frontier has atrophied catastrophically.</p> <figure> <img class="ful-img" alt="Eroom's law shows the staggering decline in drug R&amp;D productivity" id="img-eroom-1" src="/assets/img/buf.png" data-echo="/assets/img/eroom-1.png"> <figcaption id="cap-eroom-1">By 2010, a successful drug cost ten times more to develop than what it did in 1960, while 9 out of every 10 new drugs never made it to market.<span class="credits credits-blk">Jack Scannell</span></figcaption> </figure> <p>Although some aspects of this trendline were known since the 1980s, Eroom’s law was formally articulated right at its very tailend in 2012, in a seminal paper published in <em>Nature Reviews Drug Discovery</em> by four co-authors led by Jack Scannell.<sup><a href="#fn3" id="r3" class="fn-btn fn-btn-top">3</a></sup></p> <p>In a field plagued by narrow specialization, Jack Scannell is something of a renaissance man, having seen the industry from a distance and up close while working in drug research, private consulting, pharma and biotech investing, and policy advising.</p> <p>When Scannell worked as an investment analyst, he used to ask the top executives at major pharma firms why their drug R&amp;D productivity was so low. And they’d unfailingly deliver their standard answer—that it was due to the depletion of easy targets—all while deploying billions of dollars in R&amp;D every year.</p> <p>However, Scannell believes the problem lies elsewhere. There may be a host of problems one could try to fix with the industry, but Scannell’s own investigations led him to focus on a particularly serious problem that strikes at the heart of the science of drug discovery itself.</p> <p>We sit down with Jack Scannell to discuss the beginning and end of Eroom’s law, and the near frontiers of drug discovery.</p> <div class="footnotes"> <ol> <li id="fn1"> <p>A fair question to ask is: What constitutes a technology field? Taking for a start a very simple definition of technology as <em>doing more with less</em>, we believe that any field where some R&amp;D effort is undertaken to improve productivity counts as a technology area. A surprising result from using this definition is that Education, which accounts for over 5 percent of U.S. GDP spending at this point, would hardly qualify as a technology field, since so little of that spending goes to R&amp;D efforts to raise its productivity.<a href="#r1" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn2"> <p><a class="fn-ext-lnk" target="_blank" href=""></a><em>Chart of the day…or century?</em>, American Enterprise Institute, 2019 <a class="fn-ext-lnk" target="_blank" href="https://www.aei.org/carpe-diem/chart-of-the-day-or-century/">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r2" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn3"> <p><em>Diagnosing the decline in pharmaceutical R&amp;D efficiency</em>, Jack Scannell, Alex Blanckley, Helen Boldon, and Brian Warrington, Nature Reviews Drug Discovery, 2012 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/nrd3681">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r3" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s2">Beginnings</a></h2> <h3 class="head">Opposites<br>attract.</h3> </div> <p class="qst" id="q1">Your 2012 paper perfectly captured the decline that affected drug R&amp;D productivity over the previous six decades. What moved you to write it? And how did you land on the term Eroom’s law?<a class="qst-lnk" href="#q1"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>There was this nagging puzzle: Since the 1950s, lots of important R&amp;D inputs had got tens, hundreds, even billions of times cheaper, while the number of drugs approved per $1 billion spent on R&amp;D had fallen by roughly two orders of magnitude. That struck me as an ugly contrast.</p> <p>Many people bemoaned the R&amp;D productivity problem before, but not enough people had drawn attention to the contrast between input and output efficiency. I thought it was an important public policy problem, and it seemed to attract less attention than it deserved.</p> <p>I remember talking about the contrast with a friend of mine, William Baines. We chatted that drug industry productivity looked like Moore’s law backwards, and that’s how the term “Eroom’s law” was born.</p> <p class="qst" id="q2">The drug industry already knew it had an R&amp;D productivity problem. What was missing from previous attempts to diagnose the problem?<a class="qst-lnk" href="#q2"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lots of the purported diagnoses were not really diagnoses. They were attempts to sell “solutions” that, in many cases, were largely unrelated to the core problems.</p> <p>If, for example, you were an academic geneticist, the productivity problem was an opportunity to promote investment in genomics. If you were an investment bank, big pharma’s low productivity was an opportunity to promote M&amp;A. If you were a consulting firm, you might say that the reporting lines, or the business processes were wrong; things that could be fixed with a re-engineering project.</p> <p>I was working as an investment analyst. A bad prognosis can be very interesting to an analyst, because if you think an industry is in real trouble, you don’t have to own it. That meant I had a different set of biases to most people. And I didn’t have any particular solution to sell.</p> <p>We also referenced some very good prior work on the problem in the paper. Back in the 1980s, for example, there was a great paper on the R&amp;D slowdown by Fred Steward and George <span class="txt-wrap">Wibberley.<sup><a href="#fn4" id="r4" class="fn-btn fn-btn-top">4</a></sup></span></p> <p>On the whole, I think lots of people would’ve been better qualified to write the paper, but their day jobs meant they couldn’t write it.</p> <p class="qst" id="q3">Eroom's law was widely adopted after your paper came out. What was the general reaction you saw after you published?<a class="qst-lnk" href="#q3"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>People were certainly glad that someone had put names to things that they knew, or suspected, were happening already. Apart from Eroom’s law itself, people liked something else we talked about in the paper, which I called the “Better than the Beatles Problem.”</p> <p>Imagine how hard it would be to sell new pop songs if every new song had to be better than the Beatles, if you could download all the old Beatles records for free, and if no one ever got bored of listening to the same Beatles’ songs over and over again.</p> <p>That’s analogous to the problem the drug industry faces. Some old drugs are very good. They cost next to nothing when their patents expire. And doctors don’t get bored of prescribing them.</p> <p>So in many therapy areas, you end up with this ever-expanding back catalog of virtually free and very good medicine, against which any new medicine would have to compete. That reduces the value of as-yet-undiscovered drugs. It also pushes drug R&amp;D towards the areas where we don’t have a catalog of good cheap stuff; areas where R&amp;D has generated less over the last 70 years, and so is likely to be harder.</p> <p>Inevitably, people also appropriated Eroom’s Law to justify what they wanted to do anyway. That reminds me of a line from a famous British TV comedy, <em>Yes, Prime Minister</em>, which is about a hapless politician who is ruthlessly managed by his civil servants: “Something must be done. This is something. Therefore, we must do it.” I do occasionally see papers that make the same kind of argument.</p> <p>Although, to be honest, apart from a few people in the drug industry telling me that the paper became required reading, and aside from seeing the Eroom graph in a lot of presentations, it’s not clear to me that anything different was done after the paper was read.</p> <div class="footnotes"> <ol> <li id="fn4"> <p><em>Drug innovation—what's slowing it down?</em>, Fred Steward and George Wibberley, Nature, 1980 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/284118a0">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r4" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s3">Stasis</a></h2> <h3 class="head">Pay&nbsp;more.<br>Get&nbsp;less.</h3> </div> <p class="qst" id="q4">R&amp;D spending grew for decades, even as Pharma companies lost money on their investments. How did competition factor in? At what point does R&amp;D spending turn into a race to outspend everyone else?<a class="qst-lnk" href="#q4"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Returns on R&amp;D are very stochastic. The industry makes an enormous amount of its profits from a very small number of drugs, so if you think you might have one of those drugs, then you expect your returns on R&amp;D to be relatively high.</p> <p>Even for the big companies, the economics are very sensitive to one or two products, and so long as a few people in the industry are winning, it’s very hard for other people to walk away from the game.</p> <p>As a result, the industry could generate poor returns for relatively long periods of time, and few drug companies would be willing to take the painful measures they would otherwise apply if they were narrowly maximizing shareholder value.</p> <p>Today, R&amp;D spending as a percentage of sales is at an all-time high. For the big firms, it is 15-20 percent of sales versus roughly 5 percent of sales in the “golden age” of drug discovery in the 1960s. And yet, the financial returns on R&amp;D investment look to be at an all-time low.</p> <p>There’s an element of the agency problem at work here. Few people who fight their way to the top of a drug company do so because they want to fire all the scientists and pay a bigger dividend. Typically, what they really want is to discover more profitable drugs.</p> <p>So, as long as some companies in the industry seem to be doing well, firms can plausibly express confidence in their pipeline and scientists, and defend their use of shareholders money, despite the fact that, on average, they’re going to lose some of it.</p> <p>Finally, in the last decade, the debacle with a company called Valeant made R&amp;D cost-cutting less fashionable. Valeant was transparent in its opinion that the drug industry’s returns on R&amp;D were lousy, and it borrowed money to acquire a slew of other drug companies, and slashed their R&amp;D spending.</p> <p>At the same time, and away from the spotlight, Valeant was ruthless in ramping up the prices of the drugs of the companies it acquired. It was also quietly buying up pharmacy companies to make it easier to force insurance companies to cough up the cash for the drugs whose prices it had inflated.</p> <p>Valeant looked untouchable until things started to unravel very quickly in 2014–2015. The company’s behavior caught the attention of a few short sellers and journalists at first, and finally of U.S. politicians. Its pricing practices came under scrutiny, the growth evaporated, the firm was left with too much debt, and the stock price <span class="txt-wrap">cratered.<sup><a href="#fn5" id="r5" class="fn-btn fn-btn-top">5</a></sup></span></p> <p>So while the financial returns on R&amp;D may be poor, the idea that you slash R&amp;D costs in response has been discredited. No one wants to look like Valeant.</p> <p class="qst" id="q5">The standard list of fixes to raise drug R&amp;D productivity tend to focus on process efficiency and cost-cutting. Why haven’t these solutions been enough to stop and reverse Eroom’s law?<a class="qst-lnk" href="#q5"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Simply put, they’re addressing the wrong class of problems. Suppose we were looking at the oil industry, and we found that it cost a hundred times more to produce a barrel of oil today than it did in 1950, despite the fact that your technology for pumping oil out of the ground got billions of times cheaper.</p> <p>Under those circumstances, no one would say the primary problem that the oil industry has is that the reporting lines are wrong, and we need to fix the organizational structure and get the drill procurement processes sorted out. It would be obvious that there’s a geological explanation for the problem.</p> <p>When drug companies talk to their shareholders, I suspect they talk about processes and cost-cutting because that’s the sort of thing shareholders can understand. You talk less about the science and technology choices because that’s very hard to evaluate from the inside, let alone the outside.</p> <p>It’s very difficult to engage in those technical conversations, even for scientists. If you’re a cancer biologist in a drug company, it’s hard for you to assess respiratory medicine or depression. Expertise tends to be narrow.</p> <p>Even when company executives shrug their shoulders and give the standard explanation, that it’s some kind of “low-hanging fruit” problem, that’s still not a very straightforward or easy conversation to have with shareholders.</p> <p>After all, the fruit ain’t gonna get any lower. If firms primarily blame the exhaustion of some set of technological opportunities, they’re almost telling their shareholders that they should be doing a lot less R&amp;D.</p> <p class="qst" id="q6">You anticipated in your paper that Eroom's law wouldn't continue to hold, and we've seen an uptick in the number of new drug approvals in the last decade. Has the industry turned a corner?<a class="qst-lnk" href="#q6"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>FDA approvals have almost doubled in the last decade. Where we were getting 20-25 drug approvals a year before 2010, we’re running 40-50 approvals a year at the moment.</p> <p>A very large proportion of those drugs have been for oncology and for rare diseases. These two therapy areas have become attractive for a number of reasons:</p> <ol> <li>They are very price-insensitive markets, where the drug industry has discovered over time quite how much it can charge.</li> <li>The regulatory environment in those areas has been relatively benign.</li> <li>The target-based drug discovery that drug companies industrialized works better for genetically simple diseases, like orphan diseases and molecularly-defined cancer subtypes, where much of the pathology can be blamed on a single gene that you can isolate and characterize in the discovery process.</li> </ol> <p>The industry refers to such therapy areas with small patient groups as having “unmet medical needs,” which is a euphemistic way of saying that existing medicinal solutions are lacking—the inverse of the low-hanging fruit problem.</p> <p>One could try to paint a quantitative picture of the areas where there is both unmet medical need and a tractable technological opportunity. I haven’t seen that sketched out, but I suspect that if one tried to sketch it out in detail, one might find it smaller than people hope.</p> <p>Although lots of rare diseases may prove tractable, I suspect that Alzheimer’s and metastatic solid cancers will continue to be difficult to treat well with drugs. As a result, even though the post-2010 doubling in drug approvals is a great thing, it may not have the health impact of the great drugs discovered from the 1940s through the 1970s.</p> <div class="footnotes"> <ol> <li id="fn5"> <p><em>Valeant: A timeline of the big Pharma scandal</em>, Fortune, 2015 <a class="fn-ext-lnk" target="_blank" href="https://fortune.com/2015/10/31/valeant-scandal/">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r5" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2 class="title"><a id="s4">Frontiers</a></h2> <h3 class="head">Find&nbsp;a&nbsp;better<br>role&nbsp;model.</h3> </div> <p class="qst" id="q7">You've compared modern drug discovery to a ship that can sail the ocean at great speed, but never reach its destination for want of a compass. What do you think is holding back drug discovery today?<a class="qst-lnk" href="#q7"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>The rate-limiting step in drug R&amp;D has to do with what people in the drug industry call “target validation” and what I would call “screening and disease model validity.”</p> <p>Drugs are typically designed to bind a “target”; a piece of biological machinery that is thought to have some causal role in the disease you are trying to treat. Target validation is about making sure that the piece of biological machinery really does what you think it does, before you run expensive clinical trials in people.</p> <p>You can only easily experiment on the biological machinery outside of humans, whether in a test tube, in a rat, or with a bit of tissue in a dish. The logical basis of using any one of these “models” is the assumption that the performance of drug candidates in the model is correlated with their performance in sick humans.</p> <p>Of course, everyone in the drug industry knows that good models are better than bad models, but until you run the decision-theoretic maths, which too few people have done, you don’t realize that a marginally better model is 10 or even 100 times more productive than a marginally worse <span class="txt-wrap">model.<sup><a href="#fn6" id="r6" class="fn-btn fn-btn-top">6</a></sup></span></p> <p>It turns out to be deceptively hard to get people to act on the idea that something they already believe to be important—model validity—is far more important than they already believe.</p> <p>Nonetheless, British cycling has been very successful in recent years under Dave Brailsford, and his philosophy is that if you make enough marginal gains, they’ll eventually add up to a substantial improvement. Likewise, if I’m right about the correlation between model validity and R&amp;D productivity, then there should be lots of small things that could be done by drug companies that would cumulatively have a big effect.</p> <p class="qst" id="q8">If marginal differences in model quality can be orders of magnitude more predictive, why haven't we seen enough investment in better target validation tools?<a class="qst-lnk" href="#q8"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>It used to be that medicinal chemistry was the difficult bit in drug R&amp;D, and patents were great for protecting unique chemical compounds. Today, it’s target validation that’s difficult, and drug companies don’t have a great way of appropriating their work on it, because existing intellectual property protections aren’t as robust around model validity.</p> <p>A drug company could spend a $1 billion working out a new biological mechanism for Alzheimer’s and developing a wonderfully valid in vitro or in vivo model. It might even patent the model and use it to find drugs that worked in early-stage clinical trials in people.</p> <p>At that point, the basic therapeutic mechanism is proven for all to see. The target has been well and truly validated. All the other companies can then develop drugs against the same target without having to do all that investment in models.</p> <p>This is a hard problem to solve, but I do think we need to think about shifting intellectual property rights so that we incentivize the bits of R&amp;D that are difficult, like target validation, and not the bits that are comparatively easy, like medicinal chemistry.</p> <p>At present, in therapy areas like Alzheimer’s and metastatic cancer, you have expensive, low-probability, chemical roulette played out on models that everyone knows are lousy.</p> <p class="qst" id="q9">It's not uncommon for people to discover unexpected new uses for drugs in the real world. Biology reuses stuff, as you put it. So how can we rehabilitate field discovery?<a class="qst-lnk" href="#q9"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>A 2006 study that looked at this found that nearly 60 percent of new medical uses for drugs approved in a single year were discovered by practicing doctors and had little or nothing to do with drug companies or <span class="txt-wrap">universities.<sup><a href="#fn7" id="r7" class="fn-btn fn-btn-top">7</a></sup></span></p> <p>This is interesting for a number of reasons:</p> <p>First, there are only in the order of 1,400 approved drugs on which field discovery by physicians is possible, while pharma companies will have libraries of the order of 10<sup>7</sup> compounds. I suspect that doctors are able to discover new uses with a very small set of compounds because the model they observe is so valid: a real clinical response in a real patient.</p> <p>Second, field discovery happens despite the unfavorable economic incentives. While conventional drug R&amp;D enjoys tax breaks, various kinds of subsidies, good patent protection, and a tolerance for high drug prices, it’s much harder for anyone to make money from field discoveries, so the discoveries don’t get promoted to the same degree. Once a drug is on the market, for example, its patent expiry clock starts ticking, and that often makes it impractical to invest in the kind of evidence that would back up a newly-discovered use.</p> <p>Third, medical practice is heavily influenced by an approach called “Evidence-based medicine,” which holds that randomized control trials, and meta-analyses of those trials, are true and believable in a way that nothing else is, and that’s because such trials do a good job avoiding “statistical bias.”</p> <p>However, the randomized controlled trials are generally paid for by drug companies for the purposes of regulatory approval. They typically recruit young and fit patients who are much unlike the older and sicker patients who get the drugs in the real world. And the meta-analyses are based on the phase III trials the drug companies chose to run. All this means that they often lack what you might call “ecological validity.”</p> <p>Studies based on observations of patients in the real world—the kind you could do at low cost to back up a field discovery—are dismissed because they can’t rigorously eliminate statistical bias, despite the fact they’re often clear winners in terms of ecological validity.</p> <p>Why modern medicine worries more about statistical bias than ecological validity is something of a mystery to me, but the fact that it does puts field discovery at a disadvantage.</p> <p>Of course, it’s possible that new technologies could shift the balance. A world in which the response of patients to real-world pharmacology gets systematically captured and analyzed could do great things for field discovery.</p> <div class="footnotes"> <ol> <li id="fn6"> <p><em>When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis</em>, Jack Scannell and Jim Bosley, PLoS One, 2016 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1371/journal.pone.0147215">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r6" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn7"> <p>The study tracked all the new drugs approved by the FDA in 1998, and then looked at all the additional uses that those 30-or-so approved drugs acquired thereafter. It found that from 150 new medical uses, nearly 60 percent were discovered by independent practicing doctors—<em>The major role of clinicians in the discovery of off-label drug therapies</em>, Harold J. DeMonaco, Ayfer Ali, and Eric Von Hippel, Pharmacotherapy, 2006 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1592/phco.26.3.323">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r7" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr class="hr-show"> </article> <div style="display:none"><span class="essay-nav-scroll"></span><span class="essay-btn-scroll"></span></div> </main> <footer id="footer-main" class="footer footer-light"> <div class="return-top"><a href="#top"><div class="bo-aro tp-aro slv-aro u-aro"></div></a></div> <p>© 2019–<span id="current-year">2020</span> Refoundable LP</p> <ul> <li> <a href="/privacy">Privacy</a> </li> <li> <a href="/terms">Terms</a> </li> <li> <a href="/about#contact">Contact</a> </li> </ul> </footer> <script></script> <script>function stickyNav(){var e=document.getElementById("sticky-nav"),t=document.getElementsByClassName("sticky-btn");if(45<document.body.scrollTop||45<document.documentElement.scrollTop){e.classList.add("essay-nav-scroll");for(var s=0;s<t.length;s++)t[s].classList.add("essay-btn-scroll")}else for(e.classList.remove("essay-nav-scroll"),s=0;s<t.length;s++)t[s].classList.remove("essay-btn-scroll")}document.getElementById&&(onload=function(){setInterval("document.getElementById('current-year').firstChild.data = new Date().getFullYear()")})</script> <script>"serviceWorker"in navigator&&"refoundable.com"===window.location.hostname&&navigator.serviceWorker.register("/service-worker.js").then(function(e){console.log("ServiceWorker registration successful with scope: ",e.scope)}).catch(function(e){console.log("ServiceWorker registration failed: ",e)})</script> <script>!function(t,e){"function"==typeof define&&define.amd?define(function(){return e(t)}):"object"==typeof exports?module.exports=e:t.echo=e(t)}(this,function(u){"use strict";function d(t,e){if(function(t){return null===t.offsetParent}(t))return!1;var n=t.getBoundingClientRect();return n.right>=e.l&&n.bottom>=e.t&&n.left<=e.r&&n.top<=e.b}function c(){!i&&t||(clearTimeout(t),t=setTimeout(function(){s.render(),t=null},a))}var l,t,a,i,f,s={},h=function(){};return s.init=function(t){function e(t,e){return parseInt(t||e,10)}var n=(t=t||{}).offset||0,o=t.offsetVertical||n,r=t.offsetHorizontal||n;l={t:e(t.offsetTop,o),b:e(t.offsetBottom,o),l:e(t.offsetLeft,r),r:e(t.offsetRight,r)},a=e(t.throttle,250),i=!1!==t.debounce,f=!!t.unload,h=t.callback||h,s.render(),document.addEventListener?(u.addEventListener("scroll",c,!1),u.addEventListener("load",c,!1)):(u.attachEvent("onscroll",c),u.attachEvent("onload",c))},s.render=function(t){for(var e,n,o=(t||document).querySelectorAll("[data-echo], [data-echo-background]"),r=o.length,c={l:0-l.l,t:0-l.t,b:(u.innerHeight||document.documentElement.clientHeight)+l.b,r:(u.innerWidth||document.documentElement.clientWidth)+l.r},a=0;a<r;a++)n=o[a],d(n,c)?(f&&n.setAttribute("data-echo-placeholder",n.src),null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+n.getAttribute("data-echo-background")+")":n.src!==(e=n.getAttribute("data-echo"))&&(n.src=e),f||(n.removeAttribute("data-echo"),n.removeAttribute("data-echo-background")),h(n,"load")):f&&(e=n.getAttribute("data-echo-placeholder"))&&(null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+e+")":n.src=e,n.removeAttribute("data-echo-placeholder"),h(n,"unload"));r||s.detach()},s.detach=function(){document.removeEventListener?u.removeEventListener("scroll",c):u.detachEvent("onscroll",c),clearTimeout(t)},s})</script> <script>echo.init({offset:2500,throttle:250,unload:!1,callback:function(t,o){}})</script></body></html>